Apontis Pharma Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
Apontis Pharma's earnings have been declining at an average annual rate of -48.7%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 9% per year.
Key information
-48.7%
Earnings growth rate
-59.4%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | -9.0% |
Return on equity | -22.9% |
Net Margin | -17.4% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth
Oct 17Further Upside For Apontis Pharma AG (ETR:APPH) Shares Could Introduce Price Risks After 35% Bounce
Oct 17Health Check: How Prudently Does Apontis Pharma (ETR:APPH) Use Debt?
Jun 18Potential Upside For Apontis Pharma AG (ETR:APPH) Not Without Risk
Apr 05We Think Apontis Pharma (ETR:APPH) Can Afford To Drive Business Growth
Dec 02Not Many Are Piling Into Apontis Pharma AG (ETR:APPH) Stock Yet As It Plummets 27%
Jul 29Apontis Pharma's (ETR:APPH) Robust Earnings Are Supported By Other Strong Factors
Apr 08Revenue & Expenses Breakdown
How Apontis Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 41 | -7 | 18 | 0 |
31 Mar 24 | 39 | -9 | 19 | 0 |
31 Dec 23 | 37 | -11 | 21 | 0 |
30 Sep 23 | 42 | -7 | 21 | 0 |
30 Jun 23 | 46 | -3 | 21 | 0 |
31 Mar 23 | 51 | 0 | 21 | 0 |
31 Dec 22 | 56 | 3 | 20 | 0 |
30 Sep 22 | 56 | 3 | 19 | 0 |
30 Jun 22 | 56 | 4 | 17 | 0 |
31 Mar 22 | 54 | 2 | 18 | 0 |
31 Dec 21 | 51 | -1 | 20 | 0 |
30 Sep 21 | 48 | -1 | 21 | 0 |
30 Jun 21 | 46 | -1 | 22 | 0 |
31 Mar 21 | 42 | -1 | 20 | 0 |
31 Dec 20 | 39 | -1 | 18 | 0 |
31 Dec 19 | 40 | -2 | 19 | 0 |
31 Dec 18 | 20 | 0 | 8 | 0 |
Quality Earnings: APPH is currently unprofitable.
Growing Profit Margin: APPH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: APPH is unprofitable, and losses have increased over the past 5 years at a rate of 48.7% per year.
Accelerating Growth: Unable to compare APPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.4%).
Return on Equity
High ROE: APPH has a negative Return on Equity (-22.86%), as it is currently unprofitable.